The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome
Christian Buske(Helmholtz Zentrum München), Eva Hoster(Zimmer Biomet (Germany)), Martin Dreyling(LMU Klinikum), Joerg Hasford(German Medical Association), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Michael Unterhalt
Cited by 217
Related Papers
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820